gms | German Medical Science

43. Kongress der Deutschen Gesellschaft für Rheumatologie, 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 25. Wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie

02.-05. September 2015, Bremen

Poster
Posterwalk „Spondyloarthritiden I“

Meeting Abstract (SpA.03)

Patients with fibromyalgia (FM) do not fulfill classification criteria for axial spondyloarthritis (axSpA) but patients with axSpA may fulfill classification criteria for FM

Baraliakos X, Regel A, Kiltz U, Kiefer D, Menne HJ, Dybowski F, Igelmann M, Kalthoff L, Krause DMJ, Saracbasi-Zender E, Schmitz-Bortz E, Braun J
[Full Text]
Meeting Abstract (SpA.04)

Secukinumab Reduces Sacroiliac Joint and Spinal Inflammation in Patients with Ankylosing Spondylitis: MRI Data from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study (MEASURE 1)

Baraliakos X, Braun J, Sieper J, Baeten D, Readie A, Ligozio G, Richards HB
[Full Text]
Meeting Abstract (SpA.05)

Secukinumab Efficacy in Anti-TNF-Naive Patients and Patients Previously Exposed to Anti-TNF Therapy: Results of A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (MEASURE 2) in Active Ankylosing Spondylitis

Sieper J, Braun J, Baraliakos X, Baeten D, Dougados M, Emery P, Deodhar A, Porter B, Andersson M, Richards HB
[Full Text]
Meeting Abstract (SpA.06)

Intravenous Loading and Subcutaneous Maintenance with Secukinumab Provides Sustained Improvement in Multiple Measures of Disease Activity in Subjects with Active Ankylosing Spondylitis: 52-week Data from the Phase 3 MEASURE 1 study

Braun J, Wei C, Baeten D, Geusens P, Porter B, Martin R, Richards HB
[Full Text]
Meeting Abstract (SpA.07)

Secukinumab Improves Physical Function, Quality of Life, Fatigue and Work Productivity in Patients with Active Psoriatic Arthritis in FUTURE 2, A Phase 3 Trial

Schuch F, Strand V, Rahman P, McInnes I, Marzo-Ortega H, Dokoupilova E, Churchill M, Kandala S, Pricop L, Mpofu S
[Full Text]
Meeting Abstract (SpA.08)

Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52 Week Data from MEASURE 2, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing

Sieper J, Braun J, Baraliakos X, Baeten D, Dougados M, Emery P, Deodhar A, Wei C, Porter B, Andersson M, Mpofu S, Richards HB
[Full Text]
Meeting Abstract (SpA.09)

Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients With Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (FUTURE 2)

Braun J, Kavanaugh A, McInnes I, Hall S, Chinoy H, Kivitz A, Kandala S, Patekar M, Mpofu S
[Full Text]
Meeting Abstract (SpA.10)

Secukinumab is Effective in Reducing Dactylitis and Enthesitis Using Multiple Measures in Patients with Psoriatic Arthritis: Data From a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (FUTURE 2)

Wollenhaupt J, Kirkham B, McInnes I, Mease P, Kremer JM, Kandala S, Pricop L, Mpofu S
[Full Text]
Meeting Abstract (SpA.11)

Secukinumab Significantly Improves Physical Function, Quality of Life, and Work Productivity through 52 Weeks in Subjects with Active Ankylosing Spondylitis in the Phase 3 MEASURE 2 Study

Sieper J, Deodhar A, Emery P, Porter B, Andersson M, Richards HB
[Full Text]
Meeting Abstract (SpA.12)

Secukinumab Safety and Tolerability in Patients With Active Psoriatic Arthritis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials (FUTURE 1 and FUTURE 2)

Schulze-Koops H, Mease P, McInnes I, Richards HB, Pricop L, Widmer A, Mpofu S
[Full Text]
Meeting Abstract (SpA.13)

Rheumatoid Factor Status Is a Predictor of Osteoporosis in Patients with Psoriatic Arthritis

Behrens F, Köhm M, Scharbatke EC, Schmalzing M, Gnann H, Lorenz HM, Thaci D, Burkhardt HL
[Full Text]
Meeting Abstract (SpA.14)

Long-term efficacy of infliximab in patients with ankylosing spondylitis – real life data confirm the potential for dose reduction by stretching infusion intervals

Baraliakos X, Heldmann F, van den Bosch F, Burmester GR, Gaston H, van der Horst-Bruinsma I, Krause A, Schmidt RE, Schneider M, Sieper J, Bianka A, van Tubergen A, Witt M, Braun J
[Full Text]
Meeting Abstract (SpA.15)

A Randomized, Double-blind, Placebo-controlled, 16-Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis

Sieper J, van der Heijde D, Dougados M, Maksymowych W, Boice J, Bergman G, Curtis S, Tzontcheva A, Huyck S, Weng H
[Full Text]